• LAST PRICE
    1.0700
  • TODAY'S CHANGE (%)
    Trending Down-0.0400 (-3.6036%)
  • Bid / Lots
    0.8900/ 6
  • Ask / Lots
    1.1600/ 201
  • Open / Previous Close
    1.1400 / 1.1100
  • Day Range
    Low 1.0300
    High 1.1400
  • 52 Week Range
    Low 0.8400
    High 7.1500
  • Volume
    18,303
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 1.11
TimeVolumeRMTI
10:22 ET5001.14
10:26 ET10001.14
10:27 ET12031.09
11:34 ET8811.0527
12:10 ET5001.0754
12:24 ET1001.08
01:20 ET1001.0779
01:31 ET1721.0621
01:38 ET12101.07
01:42 ET26181.08
02:56 ET4311.0697
02:57 ET2001.08
03:15 ET26681.05
03:28 ET2001.07
03:30 ET2001.0601
03:32 ET24931.0639
03:46 ET4001.07
03:48 ET10001.0699
03:51 ET1001.07
03:57 ET3001.07
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesRMTI
Rockwell Medical Inc
12.9M
-0.1x
---
United StatesALIM
Alimera Sciences Inc
24.6M
-1.2x
---
United StatesSABS
SAB Biotherapeutics Inc
46.0M
-1.6x
---
United StatesBIOQ
Bioqual Inc
63.5M
12.1x
+5.80%
United StatesCDTX
Cidara Therapeutics Inc
43.0M
-1.1x
---
United StatesWUHN
M2bio Sciences Inc
2.4M
-0.1x
---
As of 2022-12-06

Company Information

Rockwell Medical, Inc. is a commercial healthcare company. The Company is focused on providing products for patients suffering from blood disorders and diseases associated with the kidney. It is developing and commercializing its technology platform, Ferric Pyrophosphate Citrate (FPC) for the transformative treatments for iron deficiency in multiple disease states. It is also a supplier of hemodialysis concentrate products to kidney dialysis clinics. The Company has developed therapies namely Triferic and Triferic AVNU from its FPC platform. Its products Triferic (dialysate) and Triferic AVNU intravenous (IV), is a therapy indicated to replace iron and maintain hemoglobin in adult hemodialysis patients. Its Triferic AVNU, is an IV formulation of Triferic, for use by hemodialysis patients. The Company’s dialysis concentrates products include CitraPure Citric Acid Concentrate, RenalPure Liquid Acid Concentrate, RenalPure and SteriLyte Bicarbonate Concentrate and Ancillary products.

Contact Information

Headquarters
30142 WIXOM ROADWIXOM, MI, United States 48393
Phone
248-960-9009
Fax
302-655-5049

Executives

Independent Chairman of the Board
Robert Radie
President, Chief Executive Officer, Director
Mark Strobeck
Chief Financial Officer, Chief Business Officer
Russell Skibsted
Senior Vice President, General Counsel, Secretary
Megan Timmins
Senior Vice President, Chief Corporate Affairs Officer
Heather Hunter

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$12.9M
Revenue (TTM)
$66.1M
Shares Outstanding
11.6M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.03
EPS
$-20.60
Book Value
$3.26
P/E Ratio
-0.1x
Price/Sales (TTM)
0.2
Price/Cash Flow (TTM)
---
Operating Margin
-39.98%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.